Clinical Trial

Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA

Study acronym: ALCYTA
Recruiting
View on ClinicalTrials.gov →
Summary
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-26; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2022-09-16
Trial Details
NCT Number NCT05354765
Lead Sponsor Institut Curie
Conditions Cancer, Immune System or Toxicities Suspected
Enrollment 300 participants
Start Date 2022-08-31
Primary Completion 2027-09-03 (estimated)
Study Completion 2027-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-06